BioScrip Inc. (NASDAQ:BIOS) rose 2.3% during mid-day trading on Friday . The stock traded as high as $2.65 and last traded at $2.63, with a volume of 58,834 shares trading hands. The stock had previously closed at $2.57.

Separately, Zacks Investment Research downgraded BioScrip from a “hold” rating to a “sell” rating in a research report on Wednesday, May 11th.

The stock’s 50 day moving average is $2.68 and its 200 day moving average is $2.49. The firm’s market cap is $300.64 million.

BioScrip (NASDAQ:BIOS) last issued its earnings results on Monday, August 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by $0.05. The firm had revenue of $232.50 million for the quarter, compared to the consensus estimate of $229.58 million. The company’s revenue was down 11.4% compared to the same quarter last year. On average, analysts predict that BioScrip Inc. will post ($0.27) EPS for the current year.

In other news, Director David W. Golding bought 12,500 shares of the company’s stock in a transaction dated Friday, June 17th. The shares were bought at an average cost of $2.48 per share, with a total value of $31,000.00. Following the acquisition, the director now owns 42,500 shares in the company, valued at $105,400. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Coliseum Capital Management, L bought 4,200,000 shares of the company’s stock in a transaction dated Wednesday, June 22nd. The stock was purchased at an average cost of $2.00 per share, for a total transaction of $8,400,000.00. The disclosure for this purchase can be found here.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.